KA
UTHR icon

Kovack Advisors’s United Therapeutics UTHR Stock Holding History

Kovack Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Sell
2,025
-4
-0.2% -$2.25K 0.05% 353
2026
Q1 		$1.2M Sell
2,029
-78
-4% -$38.8K 0.06% 310
2025
Q4 		$1.03M Buy
+2,107
New +$981K 0.05% 362

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Kovack Advisors's UTHR Position: Q2 2026 in Review

Kovack Advisors reduced its United Therapeutics (UTHR) stake by 0.2% in Q2 2026, selling an estimated $2.25K and leaving 2,025 shares worth $1.1M. The position accounts for 0.05% of the portfolio, ranked #353.

Kovack Advisors first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.2M in Q1 2026. 881 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Kovack Advisors held 2,025 shares of United Therapeutics worth $1.1M as of Q2 2026.
  • Kovack Advisors sold 4 United Therapeutics shares in Q2 2026, an estimated $2.25K.
  • United Therapeutics made up 0.05% of Kovack Advisors's portfolio in Q2 2026, its #353 holding.
  • Kovack Advisors first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Kovack Advisors's United Therapeutics position peaked at $1.2M in Q1 2026.
  • 881 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.